Code Compliance Committee

Supporting Compliance Promotion of Member Companies

Promotion of appropriate information disclosure based on Transparency Guideline

Compliance with the "Guidelines for Activities Related to Provision of Marketing Information on Ethical Drugs

Collaboration, collection, dissemination of information, and feedback with the government and related domestic and international organizations such as the Federation of Pharmaceutical Manufacturers and Associations of Japan (JPMA), Japan Fair Trade Council for Marketing of Ethical Drugs (JFTC), and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Revise the JPMA Code of Practice and disseminate it to member companies.

Conduct compliance surveys, etc. as necessary, identify issues and consider countermeasures, and support member companies in promoting compliance by holding regular training sessions, etc. (Code/Compliance Managers and Practice Managers Meetings, etc.), implementing monthly measures to promote understanding of the Code, and sending out notices as necessary. Support member companies in promoting compliance by holding regular training sessions, etc. (Code/Compliance Manager meetings, etc.), implementing measures during the code understanding promotion month, and sending notices as necessary.

Respond promptly and appropriately to inquiries, complaints, etc. related to the JPMA Code of Practice, and if necessary, take measures to request voluntary improvements from member companies that have violated the Code, and share examples of such measures with member companies to encourage the prevention of recurrence.

Support activities to increase the transparency of the relationship between member companies and medical institutions, and promote information disclosure in accordance with the Transparency Guideline.

Support appropriate information disclosure by member companies by taking necessary measures such as holding training sessions (Transparency Guideline contact person meetings) and updating FAQs to further deepen member companies' understanding of the Transparency Guideline.

As the committee in charge of guidelines for sales information provision activities for ethical drugs, the committee supports member companies' compliance with the guidelines with advice from the Advisory Council.

Confirm and review inappropriate cases in the project for monitoring sales information provision activities (commissioned by the Pharmaceutical Affairs Bureau, Ministry of Health, Labour and Welfare), and issue notices, etc. as necessary to ensure that member companies comply with the guidelines.

Collect information on relevant laws and regulations, administrative notices, etc. in a timely manner and share it with member companies.

Promote the "Consensus Framework for Ethical Collaboration in Japan" agreed upon and signed in 2018 among member companies and support the dissemination activities of related organizations in Japan in cooperation with the JFMA.

Participate in international compliance promotion activities including IFPMA Ethics & Business Integrity Committee Meeting and APEC Business Ethics for SMEs Forum 2025 to gather international trends in the pharmaceutical industry and disseminate Japanese ideas. The results obtained through these promotion activities will be fed back to the Committee and reflected in its initiatives as necessary.

Collect information on relevant laws and regulations, administrative notices, etc. in a timely manner and share it with member companies.

Revise the JPMA Code of Practice, disseminate the revised contents to member companies, and request that member companies reflect the revised contents in their own codes.